PPI-Refractory GERD (Refractory Acid Reflux)

Overview

PPI-refractory GERD refers to reflux symptoms — most commonly heartburn and regurgitation — that persist despite an adequate trial of proton pump inhibitor (PPI) therapy (Rettura et al., Frontiers in Medicine, 2021). It is one of the most common and challenging problems in reflux care: although PPIs heal lesions and relieve symptoms in the majority of patients, up to 40% of people with GERD do not respond adequately to them (Rettura et al., Frontiers in Medicine, 2021). In one U.S. survey, more than half of patients taking daily PPIs reported persistent symptoms (Fass, New England Journal of Medicine, 2022).

The central and often misunderstood point is that persistent symptoms on a PPI do not automatically mean persistent acid reflux. Many patients labeled "refractory" do not actually have acid-driven disease — their symptoms arise from reflux hypersensitivity, functional heartburn, rumination, or another esophageal disorder entirely (Katz et al., ACG Clinical Guideline, 2022). In a landmark study of 366 patients referred for PPI-refractory heartburn, exhaustive evaluation found that the heartburn was truly PPI-refractory and reflux-related in only 78 patients — about 21% (Katz et al., ACG Clinical Guideline, 2022). This distinction is the whole game: antireflux surgery and endoscopic procedures work extremely well for proven, acid-driven refractory GERD, and poorly or not at all for symptoms that are not actually reflux (Katz et al., ACG Clinical Guideline, 2022). For that reason, refractory GERD demands a careful, objective workup before any invasive treatment (see our GERD / Acid Reflux pillar for the underlying disease, and our antireflux surgery page for the surgical options) (Yadlapati et al., AGA Clinical Practice Update, 2022).

‍

Causes

Persistent symptoms despite PPI therapy fall into two broad groups (Rettura et al., Frontiers in Medicine, 2021).

True refractory GERD — ongoing pathologic reflux — can result from:

• Inadequate acid suppression, including incorrect timing (PPIs should be taken 30–60 minutes before a meal, not at bedtime), poor adherence, or rapid PPI metabolism (Katz et al., ACG Clinical Guideline, 2022).

• Weakly acidic or non-acid reflux, which a PPI cannot neutralize because the problem is the reflux of volume, not just acid (Fass, New England Journal of Medicine, 2022).

• A mechanically incompetent antireflux barrier, such as a large hiatal hernia or a weak lower esophageal sphincter, which drives reflux that medication alone cannot stop (see our Hiatal & Paraesophageal Hernia page) (Fass, New England Journal of Medicine, 2022).

Pseudo-refractory symptoms — symptoms that are not actually acid reflux — commonly reflect:

• Reflux hypersensitivity or functional heartburn, in which normal amounts of reflux generate symptoms through a hypersensitive esophagus (Katz et al., ACG Clinical Guideline, 2022).

• Other mimicking conditions, including achalasia and other motility disorders, eosinophilic esophagitis, rumination syndrome, and gastroparesis (see our Achalasia page) (Yadlapati et al., AGA Clinical Practice Update, 2022).

‍

Risk Factors

Factors that increase the likelihood of inadequate response to PPIs overlap with GERD risk factors and include (Maret-Ouda et al., JAMA, 2020):

• Obesity, which raises intra-abdominal pressure and reflux burden.

• A large hiatal hernia, a strong driver of mechanically severe, medication-resistant reflux (see our Hiatal & Paraesophageal Hernia page) (Fass, New England Journal of Medicine, 2022).

• Severe erosive esophagitis (Los Angeles grade C or D), which often requires indefinite therapy or surgery.

• Regurgitation-predominant symptoms, which respond less well to acid suppression than heartburn because the problem is reflux volume (Yadlapati et al., AGA Clinical Practice Update, 2022).

• Incorrect PPI timing or poor adherence, among the most common and correctable reasons for apparent failure (Katz et al., ACG Clinical Guideline, 2022).

• Tobacco use and nighttime/late meals (Fass, New England Journal of Medicine, 2022).

‍

How Refractory GERD Affects the Body

When reflux genuinely persists, repeated exposure of the esophageal lining to acid, bile, and gastric contents perpetuates mucosal injury and symptoms (Maret-Ouda et al., JAMA, 2020). This sustained exposure can maintain or worsen erosive esophagitis, promote peptic stricture formation, and drive the metaplastic change known as Barrett's esophagus — the precursor to esophageal adenocarcinoma (see our Barrett's Esophagus page) (Maret-Ouda et al., JAMA, 2020).

When symptoms persist without ongoing acid reflux, the mechanism is different: an esophagus sensitized to normal physiologic reflux (reflux hypersensitivity) or a brain-gut hypervigilance process (functional heartburn) generates the sensation of reflux without the tissue injury (Katz et al., ACG Clinical Guideline, 2022). These two mechanisms feel identical to the patient but respond to entirely different treatments — which is why objective testing, rather than symptoms alone, must direct therapy (Yadlapati et al., AGA Clinical Practice Update, 2022).

‍

Complications

• Erosive esophagitis and peptic stricture from uncontrolled acid exposure (Maret-Ouda et al., JAMA, 2020).

• Barrett's esophagus and esophageal adenocarcinoma — the long-term risk of inadequately controlled reflux disease, elevated particularly in those with erosive reflux (see our Barrett's Esophagus page) (Xie et al., New England Journal of Medicine, 2026).

• Impaired quality of life and high healthcare utilization, a defining feature of refractory GERD given its chronicity and impact on daily function (Rettura et al., Frontiers in Medicine, 2021).

• Inappropriate or failed procedures — when invasive antireflux treatment is performed on patients whose symptoms are not actually reflux-related, the result is persistent symptoms plus surgical risk, which is why pre-procedure confirmation is essential (Katz et al., ACG Clinical Guideline, 2022).

Symptoms and Signs

By definition, patients have persistent GERD-type symptoms despite PPI therapy (Rettura et al., Frontiers in Medicine, 2021):

• Heartburn that continues despite once- or twice-daily PPI.

• Regurgitation of acid or food — the symptom least responsive to acid suppression and most suggestive of a mechanical problem (Yadlapati et al., AGA Clinical Practice Update, 2022).

• Chest discomfort or non-cardiac chest pain.

• Extraesophageal symptoms — chronic cough, hoarseness, globus, or throat clearing, which are the least specific for reflux and the most likely to be due to another cause (Fass, New England Journal of Medicine, 2022).

Alarm features — dysphagia, unintentional weight loss, gastrointestinal bleeding or anemia, or vomiting — mandate prompt endoscopy to exclude malignancy or stricture (Maret-Ouda et al., JAMA, 2020).

‍

Diagnosis

The workup of refractory symptoms is deliberately rigorous, because its primary purpose is to prove — or disprove — that reflux is the cause before any invasive treatment (Yadlapati et al., AGA Clinical Practice Update, 2022):

• Confirm and optimize therapy first. Verify the diagnosis, confirm adherence, and correct PPI timing (30–60 minutes before meals); a potassium-competitive acid blocker such as vonoprazan is an option when acid suppression is inadequate (Katz et al., ACG Clinical Guideline, 2022; Caballero-Mateos et al., Medicina Clínica, 2026).

• Upper endoscopy (EGD) to assess for erosive esophagitis, stricture, Barrett's esophagus, eosinophilic esophagitis, and hiatal hernia (Maret-Ouda et al., JAMA, 2020).

• Ambulatory reflux monitoring (pH or pH-impedance) to objectively quantify esophageal acid exposure and symptom-reflux association — the decisive test that separates true reflux from functional disease; impedance testing additionally detects non-acid reflux (Rettura et al., Frontiers in Medicine, 2021).

• High-resolution esophageal manometry, required before any antireflux procedure to assess peristaltic function and, critically, to exclude achalasia, which can masquerade as refractory reflux (see our Achalasia page) (Yadlapati et al., AGA Clinical Practice Update, 2022).

• Barium esophagram, useful to define a hiatal hernia or anatomic abnormality when surgery is contemplated (Fass, New England Journal of Medicine, 2022).

An expert panel using objective thresholds — esophageal acid exposure time >6%, >80 reflux events, a positive symptom-reflux association, or a large (>3 cm) hiatal hernia — found these to be the findings that justify invasive therapy (Yadlapati et al., American Journal of Gastroenterology, 2018).

‍

Differential Diagnosis

Distinguishing these from true refractory GERD is the core diagnostic task (Katz et al., ACG Clinical Guideline, 2022):

• Functional heartburn — heartburn with normal acid exposure and no symptom-reflux association; does not respond to antireflux surgery and is treated with neuromodulators and behavioral therapy (Katz et al., ACG Clinical Guideline, 2022).

• Reflux hypersensitivity — normal acid exposure but a positive symptom-reflux association; a partial, not primarily surgical, target.

• Rumination syndrome — effortless regurgitation of recently eaten food with rechewing; a behavioral disorder for which surgery is explicitly not recommended (Katz et al., ACG Clinical Guideline, 2022).

• Achalasia and other motility disorders — excluded by manometry before any operation (see our Achalasia page) (Yadlapati et al., AGA Clinical Practice Update, 2022).

• Eosinophilic esophagitis — a common cause of PPI-unresponsive esophageal symptoms, diagnosed on biopsy.

• Gastroparesis and peptic ulcer disease — overlapping upper-GI symptoms.

‍

Lifestyle Modifications

Lifestyle measures remain foundational and can meaningfully reduce symptoms even when medication is insufficient (Fass, New England Journal of Medicine, 2022):

• Weight loss in overweight and obese patients — the measure with the strongest evidence (Katz et al., ACG Clinical Guideline, 2022).

• Avoiding meals within 2–3 hours of bedtime and elevating the head of the bed for nighttime symptoms (Katz et al., ACG Clinical Guideline, 2022).

• Tobacco and alcohol cessation, and avoiding individual trigger foods (Katz et al., ACG Clinical Guideline, 2022).

These measures manage symptoms but will not correct a mechanical defect such as a large hiatal hernia (see our Hiatal & Paraesophageal Hernia page) (Fass, New England Journal of Medicine, 2022).

‍

Treatment Options

Management is stepwise and strictly dependent on whether reflux has been objectively proven (Rettura et al., Frontiers in Medicine, 2021).

Medical optimization (first):

• Correct PPI timing and adherence, and consider switching PPIs or escalating to a potassium-competitive acid blocker such as vonoprazan, which provides faster, more durable acid suppression and has FDA-approved indications for erosive esophagitis and non-erosive GERD heartburn (Caballero-Mateos et al., Medicina Clínica, 2026; FDA Orange Book, 2024).

• Adjunctive agents — H2-receptor antagonists (especially at night), alginates, and, for functional overlap, neuromodulators and behavioral therapy; routine addition of medical therapies in PPI non-responders is not recommended without objective evidence of reflux (Rettura et al., Frontiers in Medicine, 2021; Katz et al., ACG Clinical Guideline, 2022).

Invasive antireflux options (only after GERD is objectively confirmed and achalasia excluded):

• Laparoscopic antireflux surgery (fundoplication) — the most established and effective durable option; a partial wrap (Toupet) is often preferred when peristalsis is impaired to limit postoperative dysphagia (see our Nissen Fundoplication page). In a network meta-analysis, laparoscopic Nissen fundoplication had the highest probability of normalizing esophageal acid exposure of any option, and in the LOTUS trial 89% of surgical patients had normal acid exposure at 5 years versus 72% on esomeprazole (Yadlapati et al., AGA Clinical Practice Update, 2022; Richter et al., Gastroenterology, 2018).

• Magnetic sphincter augmentation (LINX) — laparoscopic placement of a titanium-bead ring to augment the sphincter, recommended as an alternative to fundoplication for patients with regurgitation who fail medical management; it preserves the ability to belch and vomit (see our LINX page) (Katz et al., ACG Clinical Guideline, 2022).

• Transoral incisionless fundoplication (TIF) — an endoscopic option for carefully selected patients with troublesome regurgitation or heartburn who do not want surgery and who do not have severe esophagitis (LA grade C or D) or a hiatal hernia >2 cm (see our TIF page) (Katz et al., ACG Clinical Guideline, 2022).

• Roux-en-Y gastric bypass — the preferred antireflux operation in obese patients, addressing both reflux and weight (Yadlapati et al., AGA Clinical Practice Update, 2022).

The best surgical outcomes occur in patients with typical symptoms, abnormal acid exposure, and a good prior response to PPIs — paradoxically, complete PPI failure is a red flag that the symptoms may not be reflux at all (Katz et al., ACG Clinical Guideline, 2022).

‍

When to See a Doctor

Evaluation is warranted for heartburn, regurgitation, or chest discomfort that persists despite several weeks of correctly taken PPI therapy, and promptly for any alarm feature — difficulty swallowing, unintentional weight loss, vomiting, or signs of gastrointestinal bleeding (Maret-Ouda et al., JAMA, 2020). Reflux symptoms that have not responded to a PPI deserve formal esophageal testing rather than indefinite dose escalation, because the failure itself is a clue that the diagnosis may need revisiting (Katz et al., ACG Clinical Guideline, 2022).

‍

When to Seek Treatment

Referral for antireflux evaluation is appropriate for patients with objectively confirmed, reflux-driven symptoms that persist despite optimized medical therapy, for those with regurgitation-predominant disease that acid suppression cannot control, for severe erosive esophagitis (LA grade C or D) requiring indefinite therapy or surgery, and for patients who prefer a definitive procedure over lifelong medication (Katz et al., ACG Clinical Guideline, 2022). Patients should be referred to an experienced foregut surgeon once the diagnostic criteria for intervention are met, so the correct procedure can be matched to their anatomy and motility (Yadlapati et al., AGA Clinical Practice Update, 2022).

‍

Long-Term Outlook

Most patients with correctly diagnosed and treated refractory GERD achieve lasting symptom control, but reflux disease is chronic and requires ongoing attention. Even after successful antireflux surgery, more than 25% of patients resume some acid-suppressing medication during long-term (>5-year) follow-up, so realistic expectations and structured follow-up matter (Fass, New England Journal of Medicine, 2022). Because uncontrolled reflux can drive Barrett's esophagus over time, patients with that complication require ongoing surveillance (see our Barrett's Esophagus page) (Maret-Ouda et al., JAMA, 2020). An integrated foregut program allows reflux to be objectively monitored, procedures to be matched precisely to disease, and weight — the key modifiable factor — to be managed long-term.

‍

Prognosis

For patients with objectively proven, acid-driven refractory GERD, the prognosis after appropriate intervention is excellent: durable symptom relief and normalization of acid exposure are achieved in the large majority, with surgical control of acid exposure outperforming medication over long-term follow-up (Richter et al., Gastroenterology, 2018). For patients whose symptoms stem from functional heartburn or reflux hypersensitivity, the prognosis is also good but depends on neuromodulatory and behavioral treatment rather than surgery — which is precisely why accurate phenotyping drives outcomes (Katz et al., ACG Clinical Guideline, 2022).

Why Choose Dr. de la Cruz-Muñoz

Refractory reflux is where reflux care most often goes wrong, because persistent symptoms are frequently assumed to be acid when they are not — and operating on the wrong patient produces a failed result. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a fellowship-trained, board-certified minimally invasive foregut and bariatric surgeon in Miami with extensive experience across the full spectrum of antireflux therapy — laparoscopic and robotic fundoplication, magnetic sphincter augmentation (LINX), transoral incisionless fundoplication (TIF), hiatal and paraesophageal hernia repair, and Roux-en-Y gastric bypass as an antireflux operation. His practice insists on complete, objective evaluation — endoscopy, ambulatory reflux monitoring, and high-resolution manometry — before any intervention, so that true acid-driven refractory GERD is distinguished from functional and motility disorders, achalasia is never missed, and the right procedure is matched to each patient. Patients benefit from an integrated foregut program with durable results and structured long-term follow-up.

‍